Torbugesic

Verify with FDA CVM →

46 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
46
Total Reports
6
Deaths Reported
1300.0%
Death Rate

Active Ingredients

Torbugesic

Administration Routes

UnknownIntramuscularSubcutaneousIntravenousOralParenteral

Species Affected

Dog 33
Cat 6
Horse 6
Rat 1

Most Affected Breeds

Domestic Shorthair 5
Retriever - Labrador 5
Quarter Horse 3
Shepherd Dog - German 3
Dog (unknown) 3
Retriever - Golden 2
Terrier - Bull - Staffordshire 2
Horse (other) 2
Bichon Frise 2
Retriever (unspecified) 1

Most Reported Reactions

Polydipsia 7
Anorexia 7
Lack of efficacy - NOS 7
Polyuria 6
Other abnormal test result NOS 5
Vomiting 5
Ataxia 5
Elevated blood urea nitrogen (BUN) 4
Elevated creatinine 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Weight loss 3
Restlessness 3

Outcome Breakdown

Recovered/Normal
26 (56.5%)
Outcome Unknown
12 (26.1%)
Euthanized
3 (6.5%)
Died
3 (6.5%)
Ongoing
2 (4.3%)

Data Summary

Metric Value
Total adverse event reports 46
Reports involving death 6
Case-fatality rate (reported events) 1300.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Torbugesic Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 46 adverse event reports referencing Torbugesic, including 6 reports in which the animal died — a 1300.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Torbugesic. Reported administration routes include Unknown, Intramuscular, Subcutaneous, Intravenous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Torbugesic reports are Dog (33 reports), Cat (6 reports), Horse (6 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (5), Retriever - Labrador (5), Quarter Horse (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Torbugesic are Polydipsia (7), Anorexia (7), Lack of efficacy - NOS (7), Polyuria (6). Of the 46 reports with a coded outcome, Recovered/Normal is the leading category at 56.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Torbugesic.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial